Arbutus Biopharma Corp (NASDAQ:ABUS) price on Friday, December 27, rose 0.63% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $3.21.
A look at the stock’s price movement, the close in the last trading session was $3.19, moving within a range at $3.12 and $3.22. The beta value (5-Year monthly) was 1.916. Turning to its 52-week performance, $4.72 and $2.21 were the 52-week high and 52-week low respectively. Overall, ABUS moved -5.87% over the past month.
Arbutus Biopharma Corp’s market cap currently stands at around $608.27 million, with investors looking forward to this quarter’s earnings report slated for in January.
Analysts have a consensus estimate of 2.21M for the company’s revenue for the quarter, with a low and high estimate of 1.81M and 2.95M respectively. The average forecast suggests down to a -24.07% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 8.63M, representing a -64.96% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ABUS is a 100% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend ABUS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ABUS’s current price about -6.81% and -12.01% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 35.09, while 7-day volatility ratio is 3.03% and 4.23% in the 30-day chart. Further, Arbutus Biopharma Corp (ABUS) has a beta value of 1.78, and an average true range (ATR) of 0.14. Analysts have given the company’s stock an average 52-week price target of $8.5, forecast between a low of $8.5 and high of $8.5. Looking at the price targets, the low is -164.8% off current price level while to achieve the yearly target high, price needs to move -164.8%. Nonetheless, investors will most likely welcome a -164.8% jump to $8.5 which is the analysts’ median price.
If we refocus on Arbutus Biopharma Corp (NASDAQ:ABUS), historical trading data shows that trading volumes averaged 0.96 over the past 10 days and 868.66K over the past 3 months. The company’s latest data on shares outstanding shows there are 189.44 million shares.
The 22.22% of Arbutus Biopharma Corp’s shares are in the hands of company insiders while institutional holders own 53.48% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 5.82 million on 2024-11-29, giving us a short ratio of 6.5. The data shows that as of 2024-11-29 short interest in Arbutus Biopharma Corp (ABUS) stood at 390.0 of shares outstanding, with shares short falling to 6.54 million registered in 2024-10-31. Current price change has pushed the stock 28.40% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ABUS stock continues to rise going into the next quarter.
